Stay updated with breaking news from Bracanalysis Cdx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
02.03.2022 - SALT LAKE CITY, March 02, 2022 (GLOBE NEWSWIRE) - Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be participating in a fireside chat at the 42nd Annual Cowen ...